Table 1.
Ongoing trials.
| Clinical trial ID | Description | Intervention | Size | Status | Primary outcome |
|---|---|---|---|---|---|
| SECOND GENERATION ADT | |||||
| ARNEO trial (NCT03080116) | Interventional, single center, phase II, randomized, double-blind, placebo controlled | degarelix + apalutamide vs degarelix + placebo | 84 (estimated) | Recruiting | Minimal residual disease after 12 weeks of neoadjuvant therapy |
| ATLAS trial (NCT02531516) | Interventional, multicenter, phase III, randomized, double-blind, placebo-controlled | Apalutamide + placebo + RT vs placebo + ADT + RT | 1,503 (actual) | Not recruiting | Metastasis-free survival |
| ENZARAD trial (NCT02446444) | Interventional, phase III, randomized, open label | Enzalutamide + LHRHa + RT vs conventional NSAA + LHRHa + RT | 802 (actual) | Not recruiting | Metastasis-free survival |
| PROTEUS trial (NCT03767244) | Interventional, phase III, randomized, double-blind, placebo controlled | Apalutamide + ADT + RP + pLND vs placebo + ADT + RP + pLND | 1,500 (estimated) | Recruiting | Pathologic complete response (pCR) and metastasis-free survival |
| iPARP | |||||
| NADIR trial (NCT04037254) | Interventional, phase II, randomized, open label | ADT + IMRT vs niraparib + ADT + IMRT | 180 (estimated) | Not recruiting | Maintenance of disease-free state |
| PARTICLE THERAPY | |||||
| NCT02672449 | Prospective, multicenter, phase II, open label | Carbon ion boost followed by photon RT | 65 (estimated) | Recruiting | G3 or G4 adverse events according to the RTOG / EORTC scale |
ADT, androgen deprivation therapy; G, grade; IMRT, intensity-modulated RT; LHRHa, luteinizing hormone–releasing hormone analog; NSAA, non-steroidal anti-androgen; pCR, pathologic complete response; pLND, pelvic lymph node dissection; RP, radical prostatectomy; RT, radiotherapy.